Johnson & Johnson Gross Margin 2012-2026 | JNJ
Current and historical gross margin for Johnson & Johnson (JNJ) over the last 10 years. The current gross profit margin for Johnson & Johnson as of March 31, 2026 is %.
| Johnson & Johnson Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2026-03-31 | $96.36B | $65.36B | 67.82% |
| 2025-12-31 | $94.19B | $63.94B | 67.88% |
| 2025-09-30 | $92.15B | $62.73B | 68.08% |
| 2025-06-30 | $90.63B | $61.55B | 67.92% |
| 2025-03-31 | $89.33B | $61.01B | 68.30% |
| 2024-12-31 | $88.82B | $61.35B | 69.07% |
| 2024-09-30 | $87.70B | $60.56B | 69.05% |
| 2024-06-30 | $86.58B | $59.79B | 69.06% |
| 2024-03-31 | $85.65B | $59.27B | 69.20% |
| 2023-12-31 | $85.16B | $58.61B | 68.82% |
| 2023-09-30 | $76.31B | $53.65B | 70.30% |
| 2023-06-30 | $74.96B | $52.73B | 70.35% |
| 2023-03-31 | $77.46B | $53.77B | 69.42% |
| 2022-12-31 | $79.99B | $55.39B | 69.25% |
| 2022-09-30 | $77.21B | $54.02B | 69.96% |
| 2022-06-30 | $80.55B | $56.28B | 69.87% |
| 2022-03-31 | $79.85B | $55.91B | 70.02% |
| 2021-12-31 | $78.74B | $55.34B | 70.28% |
| 2021-09-30 | $91.45B | $61.73B | 67.51% |
| 2021-06-30 | $89.19B | $59.75B | 67.00% |
| 2021-03-31 | $84.21B | $55.79B | 66.24% |
| 2020-12-31 | $82.58B | $54.16B | 65.58% |
| 2020-09-30 | $80.86B | $53.11B | 65.68% |
| 2020-06-30 | $80.50B | $52.86B | 65.66% |
| 2020-03-31 | $82.73B | $54.73B | 66.15% |
| 2019-12-31 | $82.06B | $54.50B | 66.42% |
| 2019-09-30 | $81.71B | $54.32B | 66.49% |
| 2019-06-30 | $81.33B | $54.22B | 66.67% |
| 2019-03-31 | $81.59B | $54.50B | 66.80% |
| 2018-12-31 | $81.58B | $54.49B | 66.79% |
| 2018-09-30 | $81.38B | $53.99B | 66.35% |
| 2018-06-30 | $80.68B | $52.96B | 65.64% |
| 2018-03-31 | $78.69B | $52.05B | 66.14% |
| 2017-12-31 | $76.45B | $51.01B | 66.72% |
| 2017-09-30 | $74.36B | $50.54B | 67.97% |
| 2017-06-30 | $72.53B | $50.15B | 69.15% |
| 2017-03-31 | $72.17B | $50.31B | 69.70% |
| 2016-12-31 | $71.89B | $50.10B | 69.69% |
| 2016-09-30 | $71.60B | $49.77B | 69.52% |
| 2016-06-30 | $70.88B | $49.32B | 69.58% |
| 2016-03-31 | $70.18B | $48.60B | 69.25% |
| 2015-12-31 | $70.07B | $48.54B | 69.27% |
| 2015-09-30 | $70.52B | $48.80B | 69.20% |
| 2015-06-30 | $71.88B | $49.99B | 69.55% |
| 2015-03-31 | $73.59B | $51.02B | 69.33% |
| 2014-12-31 | $74.33B | $51.59B | 69.40% |
| 2014-09-30 | $74.43B | $51.58B | 69.30% |
| 2014-06-30 | $73.54B | $50.75B | 69.01% |
| 2014-03-31 | $71.92B | $49.68B | 69.07% |
| 2013-12-31 | $71.31B | $48.97B | 68.67% |
| 2013-09-30 | $70.52B | $48.13B | 68.25% |
| 2013-06-30 | $69.99B | $47.35B | 67.65% |
| 2013-03-31 | $68.59B | $46.29B | 67.49% |
| 2012-12-31 | $67.22B | $45.57B | 67.78% |
| 2012-09-30 | $65.92B | $44.93B | 68.15% |
| 2012-06-30 | $64.87B | $44.41B | 68.45% |
| 2012-03-31 | $65.00B | $44.50B | 68.46% |
| 2011-12-31 | $65.03B | $44.67B | 68.69% |
| 2011-09-30 | $64.42B | $44.36B | 68.86% |
| 2011-06-30 | $63.40B | $43.81B | 69.11% |
| 2011-03-31 | $62.13B | $43.09B | 69.35% |
| 2010-12-31 | $61.59B | $42.80B | 69.49% |
| 2010-09-30 | $62.49B | $43.43B | 69.49% |
| 2010-06-30 | $62.59B | $43.69B | 69.80% |
| 2010-03-31 | $62.50B | $43.78B | 70.04% |
| 2009-12-31 | $61.90B | $43.45B | 70.20% |
| 2009-09-30 | $60.53B | $43.02B | 71.08% |
| 2009-06-30 | $61.37B | $43.52B | 70.92% |
| 2009-03-31 | $62.58B | $44.43B | 71.00% |
| 2008-12-31 | $63.75B | $45.24B | 70.96% |
| 2008-09-30 | $64.52B | $45.65B | 70.75% |
| 2008-06-30 | $63.57B | $45.20B | 71.10% |
| 2008-03-31 | $62.25B | $44.27B | 71.12% |
| 2007-12-31 | $61.10B | $43.34B | 70.95% |
| 2007-09-30 | $58.82B | $41.80B | 71.06% |
| 2007-06-30 | $57.14B | $40.74B | 71.30% |
| 2007-03-31 | $55.37B | $39.54B | 71.41% |
| 2006-12-31 | $53.32B | $38.27B | 71.76% |
| 2006-09-30 | $52.25B | $37.56B | 71.89% |
| 2006-06-30 | $51.28B | $36.88B | 71.93% |
| 2006-03-31 | $50.67B | $36.55B | 72.12% |
| 2005-12-31 | $50.51B | $36.50B | 72.27% |
| 2005-09-30 | $50.66B | $36.53B | 72.11% |
| 2005-06-30 | $49.90B | $35.94B | 72.02% |
| 2005-03-31 | $48.62B | $35.02B | 72.02% |
| 2004-12-31 | $47.35B | $33.87B | 71.54% |
| 2004-09-30 | $45.85B | $32.63B | 71.16% |
| 2004-06-30 | $44.75B | $31.74B | 70.91% |
| 2004-03-31 | $43.60B | $30.78B | 70.59% |
| 2003-12-31 | $41.86B | $29.69B | 70.91% |
| 2003-09-30 | $40.01B | $28.55B | 71.35% |
| 2003-06-30 | $38.64B | $27.54B | 71.28% |
| 2003-03-31 | $37.38B | $26.66B | 71.34% |
| 2002-12-31 | $36.30B | $25.85B | 71.22% |
| 2002-09-30 | $35.12B | $24.97B | 71.09% |
| 2002-06-30 | $34.10B | $24.16B | 70.86% |
| 2002-03-31 | $33.21B | $23.48B | 70.71% |
| 2001-12-31 | $32.32B | $22.74B | 70.35% |
| 2001-09-30 | $31.20B | $21.94B | 70.31% |
| 2001-06-30 | $30.58B | $21.52B | 70.38% |
| 2001-03-31 | $30.07B | $21.12B | 70.24% |
| 2000-12-31 | $29.54B | $20.66B | 69.94% |
| 2000-09-30 | $29.30B | $20.32B | 69.35% |
| 2000-06-30 | $28.75B | $19.93B | 69.32% |
| 2000-03-31 | $28.05B | $19.41B | 69.18% |
| 1999-12-31 | $27.47B | $19.03B | 69.27% |
| 1999-09-30 | $27.06B | $18.75B | 69.29% |
| 1999-06-30 | $25.99B | $17.95B | 69.07% |
| 1999-03-31 | $24.89B | $17.14B | 68.84% |
| 1998-12-31 | $24.00B | $16.50B | 68.76% |
| 1998-09-30 | $23.16B | $15.94B | 68.82% |
| 1998-06-30 | $22.93B | $15.72B | 68.55% |
| 1998-03-31 | $22.75B | $15.60B | 68.55% |
| 1997-12-31 | $22.63B | $15.48B | 68.39% |
| 1997-09-30 | $22.50B | $17.10B | 75.98% |
| 1997-06-30 | $22.32B | $16.95B | 75.94% |
| 1997-03-31 | $22.00B | $14.93B | 67.86% |
| 1996-12-31 | $21.62B | $14.60B | 67.54% |
| 1996-09-30 | $20.96B | $12.40B | 59.13% |
| 1996-06-30 | $20.30B | $11.90B | 58.64% |
| 1996-03-31 | $19.68B | $13.17B | 66.94% |
| 1995-12-31 | $18.84B | $12.61B | 66.91% |
| 1995-09-30 | $18.09B | $12.07B | 66.72% |
| 1995-06-30 | $17.39B | $11.55B | 66.41% |
| 1995-03-31 | $16.54B | $10.98B | 66.35% |
| 1994-12-31 | $14.97B | $9.67B | 64.61% |
| 1994-09-30 | $14.41B | $9.29B | 64.45% |
| 1994-06-30 | $13.88B | $8.93B | 64.35% |
| 1994-03-31 | $13.51B | $8.70B | 64.39% |
| 1993-12-31 | $14.14B | $9.35B | 66.11% |
| 1993-09-30 | $14.11B | $9.35B | 66.23% |
| 1993-06-30 | $14.08B | $9.32B | 66.17% |
| 1993-03-31 | $13.96B | $9.23B | 66.14% |
| 1992-12-31 | $13.75B | $9.08B | 65.99% |
| 1992-09-30 | $13.40B | $8.88B | 66.31% |
| 1992-06-30 | $13.04B | $8.63B | 66.21% |
| 1992-03-31 | $12.66B | $8.37B | 66.17% |
| 1991-12-31 | $12.45B | $8.24B | 66.22% |
| 1991-09-30 | $12.00B | $7.87B | 65.61% |
| 1991-06-30 | $11.75B | $7.69B | 65.44% |
| 1991-03-31 | $11.54B | $7.48B | 64.79% |
| 1990-12-31 | $11.23B | $7.30B | 64.95% |
| 1990-09-30 | $11.00B | $7.15B | 64.98% |
| 1990-06-30 | $10.59B | $6.87B | 64.94% |
| 1990-03-31 | $10.15B | $6.60B | 65.00% |
| 1989-12-31 | $9.76B | $6.28B | 64.33% |
| 1989-09-30 | $9.49B | $6.12B | 64.50% |
| 1989-06-30 | $9.23B | $5.93B | 64.19% |
| 1989-03-31 | $9.13B | $5.82B | 63.73% |
| 1988-12-31 | $9.00B | $5.71B | 63.42% |
| 1988-09-30 | $8.73B | $5.47B | 62.65% |
| 1988-06-30 | $8.57B | $5.38B | 62.82% |
| 1988-03-31 | $8.34B | $5.27B | 63.17% |
| 1987-12-31 | $8.01B | $5.06B | 63.09% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |